Phoenix Molecular Designs Raises $2.7M To Develop PMD-026 for Triple-Negative Breast Cancer (TNBC)

Sep. 18
2018

Sept 18, 2018 - PMD-026, the first RSK inhibitor to demonstrate potential disease-modifying properties in TNBC, is now fully funded through IND

Read the full story on PR Newswire here

Previous
Previous

Phoenix Molecular Designs to Present at the Biotech Showcase 2019 Conference

Next
Next

Navigating an Ocean of Drug Development & Manufacturing Outsourcing with PhoenixMD